Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.78 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | THPO | P40225 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021935 | 0.89 | ADORA2A (0.73) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL9021920 | 0.89 | ADORA2A (0.73) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL9021645 | 0.88 | ADORA2A (0.79) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL9021625 | 0.88 | ADORA2A (0.79) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL725689 | 0.88 | CYP1A2 (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL725690 | 0.88 | CYP1A2 (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL29387702 | 0.88 | CYP1A2 (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL29753859 | 0.88 | CYP1A2 (1.00) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL9021835 | 0.86 | ADORA2A (0.77) | ADORA2AADORA2BCYP1A2THPOMEN1 | |
| SCHEMBL9022416 | 0.86 | ADORA2A (0.77) | ADORA2AADORA2BCYP1A2THPOMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| CN-1946732-A | Adenosine receptor agonists | CAMBRIDGE BIOTECHNOLOGY LTD (GB) | 2007-04-11 | — | — | CN | disclosed |
| EP-1749016-A2 | ADENOSINE RECEPTOR AGONISTS | Cambridge Biotechnology Ltd (GB) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005084653-A2 | ADENOSINE RECEPTOR AGONISTS | CAMBRIDGE BIOTECHNOLOGY LIMITED (GB) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221060-A1 | Adenosine derivatives for treatment of pain and/or inflammation; diabetes | ADORA3, ADORA2B, P2RX3 | ADORA2A 9/4885ADORA2B 2/4885CYP1A2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.